The Zhitong Finance App learned that Kingsley Biotech (01548) fell more than 6% in early trading. As of press release, it decreased by 6.45% to HK$31.64, with a turnover of HK$377 million.

According to the news, on November 5, the US White House issued a new version of the “National Policy on Nucleic Acid Synthesis and Screening” in accordance with Executive Order 14292. On November 6, the US National Institutes of Health announced that the policy is being fully implemented. When fully implemented, the policy will replace the 2024 “Nucleic Acid Synthesis Screening Framework” and other nucleic acid synthesis screening policies that conflict or are inconsistent with it.

J.P. Morgan Chase released a research report saying that Kingsley Biotech faces a manageable problem in the face of the US's updated nucleic acid screening policy, rather than fundamental demand or market entry risks. The bank believes that Kingsley has promoted responsible gene synthesis practices for many years and self-certified that it complies with the US nucleic acid synthesis screening framework in 2024; in addition, gene synthesis revenue from US federally funded projects is expected to have limited impact on Kingsley's gene synthesis business.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.